None(BPT) - This article was sponsored and developed by Neurocrine Biosciences, Inc. Cerebral palsy (CP) is a neurodevelopmental disorder affecting movement and posture that begins in early childhood development. It is the most common cause of motor disability in children, affecting about one in 345 children in the United States. 1-2 It may happen as a result of lack of oxygen during or around birth, stroke, infection, a problem with metabolism or other problems that cause injury or affect the development of parts of the brain involved in movement control in the first few years of life. 3 CP is a permanent condition, affecting a person for their entire life. People living with CP typically have motor problems, which may include spasticity (abnormal muscle tightness), dyskinesia (uncontrolled movements) or ataxia (poor muscle control), and many people have a mix of these motor disorders. 4 Dyskinesia due to CP (DCP) is one of the most disabling forms of CP and impacts approximately 10% to 20% of people living with CP. 5-6 According to the Cerebral Palsy Foundation (CPF), the combination of irregular and unpredictable movements (chorea) and twisting and repeating movements (dystonia) often disrupt activities and cause significant functional impairment, including the ability to maintain balance, walk or fine motor control. 7 Heather Riordan, M.D., Neurologist and Movement Disorders Specialist, Director of the Phelps Center for Cerebral Palsy at the Kennedy Krieger Institute, discusses the symptoms of chorea and impact on patients in a video shared on the CPF website here . About 30% of people with DCP are affected mostly by these involuntary and irregular movements (chorea), while dystonia is the predominant motor finding in the remaining 70%. 8 However, it is common for both chorea and dystonia movements to be present together. 6 For people living with DCP, these movements can occur in any region of the body, including the arms and legs, torso and face and may vary in severity. They are often triggered or made worse by stimulation or stress. Because dyskinesia can occur at rest and/or when actively using the body, the problems with movement are very burdensome in day-to-day living, with discomfort and pain affecting the quality of life for people and their caregivers. 9 Jen Lyman, mom to a son with DCP, highlights how dyskinesia makes communicating more difficult. "The most difficult thing about dyskinesia is watching my son struggle to do things that he wants to do, but the extra movements get in the way...special things, such as using a touch screen to video chat with his grandmother, are nearly impossible despite his best efforts to use his hands and fingers. Something so simple, yet so special for him should be effortless." DCP has a wide-ranging impact on the individual, including lifelong challenges with movement, a higher risk of other medical issues, a higher rate of mental health challenges and difficulties with communication. 10-12 "Those of us who have the privilege to serve patients with dyskinetic, hyperkinetic or mixed cerebral palsy see the functional impact of this very challenging type of tone every day," said Susan Biffl, M.D., Rehabilitation Medicine Specialist at Rady Children's Hospital-San Diego and Assistant Professor at UC San Diego School of Medicine. "Patients face challenges with self-care, independence, mobility, communication, fine motor skills that affect occupational and recreational activities, swallowing, social interactions and even sleep. As this tone is variable, it is much more challenging to treat than more consistent tone issues, such as spasticity." Treatment Options There are currently no Food and Drug Administration-approved treatments for DCP. Dystonia and chorea are often managed separately as they respond differently to various treatments, which can make treatment challenging. 3 Most drugs being investigated for DCP have focused on dystonia, and more research is needed to determine potential treatments for chorea. New treatment options are needed to help manage these movement disorders and improve daily function and quality of life for those affected. "After 20 years of caring for individuals with cerebral palsy, I continue to find those with dyskinetic cerebral palsy among the most challenging to treat, largely due to the limited effectiveness of available pharmacologic options," said Joyce Oleszek, M.D., Professor, Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine. "There is an urgent need for more robust evidence to support pharmacologic treatments for this condition, given its profound impact on function, comfort and quality of life." Ongoing Research Clinical studies are important in the development of treatment options, allowing researchers to evaluate the safety and effectiveness of new medicines. The data from clinical studies are used to determine if an investigational treatment can be approved for use to treat certain disorders. There are ongoing clinical studies evaluating potential treatments for DCP, including one for chorea. Neurocrine Biosciences is conducting the KINECT ® -DCP clinical study, a Phase 3, randomized, double-blind placebo-controlled study investigating the study drug, valbenazine, for the treatment of DCP. The clinical study is currently enrolling children, adolescents and adults six to 70 years of age who have been diagnosed with DCP. "The Cerebral Palsy Foundation is excited to partner with Neurocrine Biosciences on this study," said Rachel Byrne, Executive Director of the Cerebral Palsy Foundation. "We are proud to support strong research that can potentially bring meaningful change to the lives of those living with cerebral palsy." If you or someone you know may be eligible for this research study, please visit the study website for additional information here: FindADCPStudy.com . REFERENCES © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-NBI-US-0115 12/2024 NBI-98854-DCP3018_11DecMatRelease_v1.0_25November2024
LeBron James says he’s taking a social media break for nowJosh Allen makes his final MVP case — or at least it should be
JPMorgan Chase & Co. lifted its holdings in shares of iShares S&P 100 ETF ( NYSEARCA:OEF – Free Report ) by 0.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,494,935 shares of the company’s stock after purchasing an additional 13,236 shares during the period. JPMorgan Chase & Co.’s holdings in iShares S&P 100 ETF were worth $413,739,000 as of its most recent filing with the SEC. A number of other large investors also recently added to or reduced their stakes in OEF. Quotient Wealth Partners LLC increased its holdings in shares of iShares S&P 100 ETF by 1.1% in the third quarter. Quotient Wealth Partners LLC now owns 3,620 shares of the company’s stock worth $1,002,000 after buying an additional 39 shares during the period. Soltis Investment Advisors LLC increased its stake in iShares S&P 100 ETF by 4.9% in the 3rd quarter. Soltis Investment Advisors LLC now owns 856 shares of the company’s stock worth $237,000 after purchasing an additional 40 shares during the period. Concurrent Investment Advisors LLC increased its stake in iShares S&P 100 ETF by 1.1% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 3,814 shares of the company’s stock worth $1,055,000 after purchasing an additional 41 shares during the period. Harbour Investments Inc. lifted its position in iShares S&P 100 ETF by 5.1% in the third quarter. Harbour Investments Inc. now owns 845 shares of the company’s stock valued at $234,000 after purchasing an additional 41 shares during the last quarter. Finally, JFS Wealth Advisors LLC boosted its stake in shares of iShares S&P 100 ETF by 0.7% during the third quarter. JFS Wealth Advisors LLC now owns 6,288 shares of the company’s stock valued at $1,740,000 after purchasing an additional 44 shares during the period. iShares S&P 100 ETF Stock Down 1.1 % Shares of NYSEARCA OEF opened at $293.88 on Friday. The company has a market cap of $14.17 billion, a price-to-earnings ratio of 28.76 and a beta of 1.04. The firm’s fifty day moving average is $288.50 and its 200 day moving average is $275.44. iShares S&P 100 ETF has a 52 week low of $219.38 and a 52 week high of $298.44. About iShares S&P 100 ETF iShares S&P 100 ETF, formerly iShares S&P 100 Index Fund (the Fund), is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P 100 Index (the Index). The Index measures the performance of the large-capitalization sector of the United States equity market and consists of blue chip stocks from diverse industries in the S&P 500 Index. Read More Want to see what other hedge funds are holding OEF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares S&P 100 ETF ( NYSEARCA:OEF – Free Report ). Receive News & Ratings for iShares S&P 100 ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares S&P 100 ETF and related companies with MarketBeat.com's FREE daily email newsletter .The China Fund, Inc. Declares Distributions
Dyskinetic Cerebral Palsy: A Closer Look at Symptoms, Diagnosis and Clinical Research UnderwayFormer president Jimmy Carter passed away at age 100 on December 29. He is survived by his four children; Amy, Donnel, John and James and 11 grandchildren, and 14 great-grandchildren. Carter lived out the latter years of his life with his enormous family. In conversation with CNN in 2015, he said, "Our family has grown. There are 38 of us in total, including 22 grandchildren and great-grandchildren. So, we try to hold our family together and just enjoy the family life." All About Carter's Children John William “Jack” Carter is the eldest son of Jimmy and Rosalynn Carter who is 77 years old. The second oldest son, James Earl "Chip" Carter III, 74, inherited his father's and grandfather's names. The youngest of the Carter brothers is 72-year-old Donnel "Jeff" Carter. The 57-year-old Amy Carter is the former president and first lady's only daughter and youngest child by 15 years. John Carter: Born in 1947, John joined the Navy in 1968 and left in 1970. Prior to following in his father's footsteps and running for the U.S. Senate in 2006, he had positions at CitiBank and the Chicago Board of Trade. James Carter: Born in 1950, James was involved in politics, having worked at the Democratic National Committee and on the Plains City Council. He was elected Friendship Force president in 2000. Donnel Carter: Born in 1952, Donnel worked as a researcher for the Carter Center's Conflict Resolution Program and cofounded Computer Mapping Consultants. He is also the author of 'Ancestors of Jimmy and Rosalynn Carter, a look at the Carter family history.' Amy Carter: Born in 1967, Amy gained notoriety for her political involvement, which included taking part in sit-ins and demonstrations against South Africa's apartheid and US foreign policy in Central America. Get Latest News Live on Times Now along with Breaking News and Top Headlines from US News, World and around the world.
NFC-leading Lions host Bears on Thanksgiving, trying to stop 7-game losing streak on the holiday
How to Watch Top 25 Women’s College Basketball Games – Sunday, December 1
The acquisition of Italian giant Aerospace by the Turkish unmanned combat aerial vehicle producer marks a milestone for the Turkish industry, according to experts. Founded in 1884, Piaggio Aerospace is best known for producing P.180 Avanti business jets, and aircraft engines. Italy last week approved the sale of the company to Baykar. “This is a remarkable development for [the Turkish aviation sector],” commented Erdoğan Karakuş, a retired lieutenant general. Piaggio is a well-established company that has a certain level of aircraft construction capability and engine technology, he said, noting that Türkiye is not currently building small-scale passenger airplanes. “One of the issues we face is engine production. In this respect, this is a remarkable development,” Karakuş furthered. “Through this company [Piaggio Aerospace], we can produce fire-fighting aircraft and propeller-driven aircraft for short-distance flights,” he explained. This cooperation will take Baykar to better places, said Güray Alpar, a retired major general, welcoming the deal as a “wise decision.” “We are ahead in some areas. It [the acquisition of Piaggio] will benefit both sides,” Alpar commented, adding that this may open new doors to cooperation between the two countries in many areas. Technology sharing is the key issue in this deal, according to Alpar, who also pointed out the problems Türkiye is having with developing engines.A small group of stocks could capture the next burst of AI development, BofA said. The firm sees a coming "Agentic AI wave," which includes developments like AI-powered apps and robots. Strategists highlighted six large-cap stocks that represent its top picks for the next wave. A new wave of AI development is about to take shape — and Wall Street is starting to divert its attention from the market's largest companies to a different group of stocks, according to Bank of America. In a recent note, the bank's strategists said they foresaw a coming "Agentic AI wave," referring to the second phase of artificial intelligence development. Possible beneficiaries include companies that are beginning to deploy AI through apps, or industrial and commercial robots. There are some signs AI innovation is already headed in that direction, the bank added, pointing to new features added to AI software, like Google's Gemini , and robotic security dogs being deployed at Trump's Florida Mar-a-Lago. Meanwhile, Bank of America clients are already beginning to shift their focus from the market's top AI names, like Nvidia , to what the bank believes to be the "second phase of AI beneficiaries," the note said. "We urge investors not to diminish AI's near-term disruption potential in this early stage. Upside is unlikely to be fully priced in across the AI investment stack and, specifically, across our software coverage, in our view," strategists wrote. "We expect AI monetization across our coverage to begin in 2025 as software's AI moment arrives and monetization to become meaningful in 2026 as enterprise adoption accelerates," they continued. The bank reiterated its focus on six large-cap stocks, which it said were among its top picks as the Agentic AI theme plays out. 1. Microsoft ( MSFT ) In an early November note, the bank pointed to Microsoft's plans to supplement Copilot with more AI agents, which could help automate tasks related to sales, services, finances, and managing supply chains. Strategists issued a price target of $510 a share, implying 23% upside from current levels. 2. Salesforce ( CRM ) Salesforce plans on integrating AI agents into its range of products, which can help automate tasks in areas like customer service and marketing, the bank said. The firm also finalized a partnership with Nvidia to create avatars that can automate tasks in customer service, crisis management, and other areas. Strategists issued a price target of $390 a share, implying 14% upside from current levels. 3. Adobe ( ADBE ) Adobe is planning to work AI tools into its product suite, including its Creative Cloud and Experience Cloud platforms. That can help automate tasks related to data analysis and creating new content, strategists said. Bank of America issued a price target of $640 a share, implying 20% upside from current levels. 4. ServiceNow ( NOW ) The company is planning to deploy AI agents on its Now Platform, which can help in areas like IT management and customer service. Strategists issued a price target of $1,075 a share, implying 1% upside from current levels. 5. Intuit ( INTU ) Intuit is also planning to integrate its AI agent across its range of products, which includes TurboTax, Credit Karma, and QuickBooks. That can automate tasks for users and businesses, like creating new bills or processing invoices. Strategists issued a price target of $780 a share, implying 21% upside from current levels. 6. HubSpot ( HUBS ) The firm is planning to deploy an AI agent into its Marketing and Content Hub, which will help automate tasks in areas like marketing and sales. Strategists issued a price target of $780 a share, implying 6% upside from current levels.
None
On Friday, Russian President Vladimir Putin declared the ongoing testing of the country's latest military innovation, the Oreshnik hypersonic missile, promising that a stock is ready for combat scenarios. This statement followed Ukraine's report of working on developing air defense systems to counter the burgeoning threat. The launch of this new intermediate-range weapon into Ukraine marks a significant escalation, described by Ukrainian President Volodymyr Zelenskiy as a breach, aided by Western allies, in creating systems to mitigate new risks. This move is seen as a response to Ukraine's deployment of U.S. and British missiles against Russian targets. Experts highlighted the Oreshnik's innovative design, which allows it to carry multiple warheads to strike various targets simultaneously, echoing capabilities of longer-range missiles. As tensions rise with Western countries, the missile's firing acts as a stern warning from Moscow, urging restraint against further involvement in the Ukraine conflict. (With inputs from agencies.)Worst places in the US to cash Social Security checks in 2025 – Neither California nor New York(BPT) - This article was sponsored and developed by Neurocrine Biosciences, Inc. Cerebral palsy (CP) is a neurodevelopmental disorder affecting movement and posture that begins in early childhood development. It is the most common cause of motor disability in children, affecting about one in 345 children in the United States. 1-2 It may happen as a result of lack of oxygen during or around birth, stroke, infection, a problem with metabolism or other problems that cause injury or affect the development of parts of the brain involved in movement control in the first few years of life. 3 CP is a permanent condition, affecting a person for their entire life. People living with CP typically have motor problems, which may include spasticity (abnormal muscle tightness), dyskinesia (uncontrolled movements) or ataxia (poor muscle control), and many people have a mix of these motor disorders. 4 Dyskinesia due to CP (DCP) is one of the most disabling forms of CP and impacts approximately 10% to 20% of people living with CP. 5-6 According to the Cerebral Palsy Foundation (CPF), the combination of irregular and unpredictable movements (chorea) and twisting and repeating movements (dystonia) often disrupt activities and cause significant functional impairment, including the ability to maintain balance, walk or fine motor control. 7 Heather Riordan, M.D., Neurologist and Movement Disorders Specialist, Director of the Phelps Center for Cerebral Palsy at the Kennedy Krieger Institute, discusses the symptoms of chorea and impact on patients in a video shared on the CPF website here . About 30% of people with DCP are affected mostly by these involuntary and irregular movements (chorea), while dystonia is the predominant motor finding in the remaining 70%. 8 However, it is common for both chorea and dystonia movements to be present together. 6 For people living with DCP, these movements can occur in any region of the body, including the arms and legs, torso and face and may vary in severity. They are often triggered or made worse by stimulation or stress. Because dyskinesia can occur at rest and/or when actively using the body, the problems with movement are very burdensome in day-to-day living, with discomfort and pain affecting the quality of life for people and their caregivers. 9 Jen Lyman, mom to a son with DCP, highlights how dyskinesia makes communicating more difficult. "The most difficult thing about dyskinesia is watching my son struggle to do things that he wants to do, but the extra movements get in the way...special things, such as using a touch screen to video chat with his grandmother, are nearly impossible despite his best efforts to use his hands and fingers. Something so simple, yet so special for him should be effortless." DCP has a wide-ranging impact on the individual, including lifelong challenges with movement, a higher risk of other medical issues, a higher rate of mental health challenges and difficulties with communication. 10-12 "Those of us who have the privilege to serve patients with dyskinetic, hyperkinetic or mixed cerebral palsy see the functional impact of this very challenging type of tone every day," said Susan Biffl, M.D., Rehabilitation Medicine Specialist at Rady Children's Hospital-San Diego and Assistant Professor at UC San Diego School of Medicine. "Patients face challenges with self-care, independence, mobility, communication, fine motor skills that affect occupational and recreational activities, swallowing, social interactions and even sleep. As this tone is variable, it is much more challenging to treat than more consistent tone issues, such as spasticity." Treatment Options There are currently no Food and Drug Administration-approved treatments for DCP. Dystonia and chorea are often managed separately as they respond differently to various treatments, which can make treatment challenging. 3 Most drugs being investigated for DCP have focused on dystonia, and more research is needed to determine potential treatments for chorea. New treatment options are needed to help manage these movement disorders and improve daily function and quality of life for those affected. "After 20 years of caring for individuals with cerebral palsy, I continue to find those with dyskinetic cerebral palsy among the most challenging to treat, largely due to the limited effectiveness of available pharmacologic options," said Joyce Oleszek, M.D., Professor, Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine. "There is an urgent need for more robust evidence to support pharmacologic treatments for this condition, given its profound impact on function, comfort and quality of life." Ongoing Research Clinical studies are important in the development of treatment options, allowing researchers to evaluate the safety and effectiveness of new medicines. The data from clinical studies are used to determine if an investigational treatment can be approved for use to treat certain disorders. There are ongoing clinical studies evaluating potential treatments for DCP, including one for chorea. Neurocrine Biosciences is conducting the KINECT ® -DCP clinical study, a Phase 3, randomized, double-blind placebo-controlled study investigating the study drug, valbenazine, for the treatment of DCP. The clinical study is currently enrolling children, adolescents and adults six to 70 years of age who have been diagnosed with DCP. "The Cerebral Palsy Foundation is excited to partner with Neurocrine Biosciences on this study," said Rachel Byrne, Executive Director of the Cerebral Palsy Foundation. "We are proud to support strong research that can potentially bring meaningful change to the lives of those living with cerebral palsy." If you or someone you know may be eligible for this research study, please visit the study website for additional information here: FindADCPStudy.com . REFERENCES © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-NBI-US-0115 12/2024 NBI-98854-DCP3018_11DecMatRelease_v1.0_25November2024
2024 Black Friday online shopping sets massive recordBOSTON , Dec. 13, 2024 /PRNewswire/ -- The Board of Directors (the "Board") of The China Fund, Inc. (the "Fund") has declared a distribution in the amount of $0.1497 per share. The distribution is comprised entirely of ordinary income. The dividend will be payable on January 10, 2025 , to stockholders of record on December 30, 2024 , with an ex-dividend date of December 30, 2024 . The Fund has a Dividend Reinvestment and Cash Purchase Plan (the "Plan") in which each stockholder automatically participates, unless the stockholder instructs Computershare Trust Company, N.A. (the "Plan Agent"), in writing, to have all distributions, net of any applicable U.S. withholding tax, paid in cash. If the Fund's shares are trading at a premium to the net asset value ("NAV") per share of the Fund on the distribution payment date, the Plan provides that stockholders will be issued Fund shares valued at NAV. If the Fund's shares are trading at a discount to the NAV per share, stockholders will be issued shares of the Fund valued at market price. Stockholders will not be charged a fee in connection with the reinvestment of dividends or capital gains distributions. A stockholder may terminate his or her participation in the Plan by notifying the Plan Agent in writing at the address below. Stockholders who have questions regarding the distribution may contact EQ Fund Solutions, LLC at 1-888-CHN-CALL (246-2255). The Fund is a closed-end management investment company with the objective of seeking long-term capital appreciation by investing primarily in equity securities (i) of companies for which the principal securities trading market is in the People's Republic of China (" China "), or (ii) of companies for which the principal securities trading market is outside of China , or constituting direct equity investments in companies organized outside of China , that in both cases derive at least 50% of their revenues from goods and services sold or produced, or have at least 50% of their assets, in China . While the Fund is permitted to invest in direct equity investments of companies organized in China , it presently holds no such investments. The Fund's shares are listed on the New York Stock Exchange under the ticker symbol "CHN." The Fund's investment manager is Matthews International Capital Management, LLC. For more information regarding the Fund and the Fund's holdings, please call 1-888-CHN-CALL (246-2255) or visit the Fund's website at www.chinafundinc.com . For more information about the Plan or to terminate your participation in the Plan, please contact Computershare Trust Company, N.A. at c/o The China Fund, Inc. at P.O. Box 43078, Providence, Rhode Island 02940-3078, by telephone at 1-800-426-5523 or via the Internet at www.computershare.com/investor . View original content: https://www.prnewswire.com/news-releases/the-china-fund-inc-declares-distributions-302331625.html SOURCE The China Fund, Inc.
